Cryoglobulinemic Vasculitis

Complex MONDO:0007407 Pathograph 6 Vascular disorder

Cryoglobulinemic vasculitis is an immune-complex mediated small-vessel vasculitis characterized by circulating cryoglobulins. Pathogenic cryoglobulins and B-cell clones form immune complexes that deposit on vascular endothelium, activate inflammatory pathways, and produce purpura, arthralgia, arthritis, peripheral neuropathy, glomerulonephritis, and other systemic manifestations.

Ask OpenScientist

Ask a research question about Cryoglobulinemic Vasculitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
1
Histopath.
10
Phenotypes
6
Pathograph
5
Treatments
3
Subtypes
1
Deep Research
◆

Subtypes

3
Type I cryoglobulinemic vasculitis
Type I disease is associated with immunoglobulins without rheumatoid-factor activity and often reflects monoclonal cryoglobulins from B-cell lymphoproliferative disease.
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"immune complexes composed of rheumatoid factor (RF) monoclonal or polyclonal against polyclonal IgG (type II or type III cryoglobulins, respectively) or immunoglobulins without RF activity (type I)"
This defines type I cryoglobulins separately from mixed type II and III cryoglobulins.
Type II mixed cryoglobulinemic vasculitis
Type II mixed disease contains monoclonal rheumatoid factor activity against polyclonal IgG and is frequently associated with chronic hepatitis C infection or other B-cell stimulation.
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"immune complexes composed of rheumatoid factor (RF) monoclonal or polyclonal against polyclonal IgG (type II or type III cryoglobulins, respectively)"
This defines type II and type III mixed cryoglobulins as RF-containing immune complexes against polyclonal IgG.
Type III mixed cryoglobulinemic vasculitis
Type III mixed disease contains polyclonal rheumatoid-factor activity against polyclonal IgG and is often linked to autoimmune or chronic inflammatory immune stimulation.
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"immune complexes composed of rheumatoid factor (RF) monoclonal or polyclonal against polyclonal IgG (type II or type III cryoglobulins, respectively)"
This defines type II and type III mixed cryoglobulins as RF-containing immune complexes against polyclonal IgG.
⚙

Pathophysiology

4
Cryoglobulin immune-complex vascular deposition
Circulating cryoglobulins form pathogenic immune complexes that deposit on small-vessel endothelium and can trigger vasculitis or occlusive vasculopathy, especially in susceptible tissues and organs.
endothelial cell link
Downstream
Immune-complex small-vessel vascular injury Immune-complex deposition activates inflammatory pathways and recruits leukocytes to small-vessel walls.
Show evidence (2 references)
PMID:37916482 SUPPORT Human Clinical
"Cryoglobulinemic vasculitis (CV) is an immune complex mediated small vessel vasculitis characterized by the presence of cryoglobulins in serum, often associated with hepatitis C infection, systemic autoimmune diseases or hematological conditions."
This review directly defines CV as an immune-complex small-vessel vasculitis with circulating cryoglobulins.
PMID:33186245 SUPPORT Human Clinical
"In vivo, in cold exposed tissues and organs, they can induce vasculitis and occlusive vasculopathy after deposition on vascular endothelium under low temperature and high concentration conditions."
This supports endothelial deposition of cryoglobulins as a vascular lesion mechanism.
B-cell clonal immune-complex production
In infectious and noninfectious type II or type III disease, pathogenic B-cell clones produce immune complexes that drive small-vessel vasculitis; this explains the therapeutic rationale for antiviral removal of B-cell stimulation and anti-CD20 B-cell depletion.
B cell link
B cell proliferation link ↑ INCREASED immunoglobulin production link ↑ INCREASED
Downstream
Cryoglobulin immune-complex vascular deposition Pathogenic B-cell clones provide the immune-complex substrate for vascular deposition and inflammation.
Show evidence (1 reference)
PMID:37916482 SUPPORT Human Clinical
"Specific B-cell clones are involved in the production of pathogenic immune complexes that leads to small-vessel vasculitis."
This supports pathogenic B-cell immune-complex production as a disease mechanism.
Immune-complex small-vessel vascular injury
Immune-complex deposition, complement consumption, and polymorphonuclear neutrophil activation are associated with vessel-wall inflammation, producing purpura, neuropathy, renal disease, and other systemic small-vessel manifestations.
neutrophil link
complement activation, classical pathway link ↑ INCREASED
Show evidence (2 references)
DOI:10.3389/fmed.2023.1103065 SUPPORT Human Clinical
"Serum sickness and CV fulfill the criteria of a type III hypersensitivity immune reaction as large lattices of the IC precipitate at vessel walls and activate polymorphonuclear neutrophils (PMNs)."
This directly supports immune-complex precipitation at vessel walls with neutrophil activation in CV.
PMID:18796155 SUPPORT Human Clinical
"Circulating mixed cryoglobulins, low C4 levels and orthostatic skin purpura are the hallmarks of the disease. Leukocytoclastic vasculitis involving medium- and, more often, small-sized blood vessels is the typical pathological finding, easily detectable by means of skin biopsy of recent..."
Low C4 supports complement consumption, while leukocytoclastic small-vessel vasculitis supports the downstream vascular-injury phenotype.
Cryoprotein occlusive vasculopathy and hyperviscosity
Type I cryoglobulinemic vasculitis can include a cryoprotein-dominant occlusive vasculopathy and hyperviscosity presentation in addition to inflammatory small-vessel vasculitis.
endothelial cell link
Downstream
Hyperviscosity syndrome Cryoprotein vascular effects can manifest clinically as hyperviscosity syndrome.
Show evidence (2 references)
PMID:33186245 PARTIAL Human Clinical
"In vivo, in cold exposed tissues and organs, they can induce vasculitis and occlusive vasculopathy after deposition on vascular endothelium under low temperature and high concentration conditions."
This supports cryoglobulin deposition causing occlusive vasculopathy at vascular endothelium.
PMID:21571735 PARTIAL Human Clinical
"vascular involvement (purpura, skin ulcers, necrotic skin lesions or necrotising vasculitis biopsy-proven, Raynaud's phenomenon, or hyperviscosity syndrome according to clinical features and plasma viscosity test)"
This supports hyperviscosity syndrome as a vascular manifestation considered in CV classification.
✶

Histopathology

1
Biopsy-proven necrotising vasculitis
Biopsy evidence of necrotising vasculitis is a clinical classification item for cryoglobulinemic vasculitis.
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"vascular involvement (purpura, skin ulcers, necrotic skin lesions or necrotising vasculitis biopsy-proven, Raynaud's phenomenon, or hyperviscosity syndrome according to clinical features and plasma viscosity test)"
This classification item supports biopsy-proven necrotising vasculitis as a diagnostic histopathologic finding.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Cryoglobulinemic Vasculitis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Cardiovascular 2
Livedo reticularis Livedo reticularis (HP:0033505)
Show evidence (1 reference)
PMID:33186245 SUPPORT Human Clinical
"Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs)."
This review explicitly lists livedo reticularis among cutaneous manifestations of CV.
Raynaud phenomenon Raynaud phenomenon (HP:0030880)
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"vascular involvement (purpura, skin ulcers, necrotic skin lesions or necrotising vasculitis biopsy-proven, Raynaud's phenomenon, or hyperviscosity syndrome according to clinical features and plasma viscosity test)"
This classification item explicitly includes Raynaud phenomenon as vascular involvement in CV.
Integument 1
Skin ulcer Skin ulcer (HP:0200042)
Show evidence (1 reference)
PMID:33186245 SUPPORT Human Clinical
"Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs)."
This review lists ulcers among cutaneous manifestations.
Musculoskeletal 1
Arthritis Arthritis (HP:0001369)
Show evidence (1 reference)
PMID:33186245 SUPPORT Human Clinical
"Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs)."
This review lists arthritis among rheumatologic manifestations.
Nervous System 1
Peripheral neuropathy Peripheral neuropathy (HP:0009830)
Show evidence (1 reference)
PMID:33186245 SUPPORT Human Clinical
"Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs)."
This directly supports peripheral neuropathy in CV.
Constitutional 2
Fatigue Fatigue (HP:0012378)
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"Constitutional symptoms fatigue, low-grade fever (37–37.9°C for more than 10 days) or fever (≥38°C), or fibromyalgia,16 articular involvement"
This classification item supports fatigue as a constitutional manifestation of cryoglobulinemic vasculitis.
Arthralgia Arthralgia (HP:0002829)
Show evidence (1 reference)
PMID:33186245 SUPPORT Human Clinical
"Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs)."
This review lists arthralgia among rheumatologic manifestations.
Other 3
Palpable purpura Palpable purpura (HP:0031363)
Show evidence (1 reference)
PMID:33186245 SUPPORT Human Clinical
"Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs)."
This directly supports purpura as a cutaneous manifestation of CV.
Hyperviscosity syndrome
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"vascular involvement (purpura, skin ulcers, necrotic skin lesions or necrotising vasculitis biopsy-proven, Raynaud's phenomenon, or hyperviscosity syndrome according to clinical features and plasma viscosity test)"
This classification item explicitly includes hyperviscosity syndrome as vascular involvement in CV.
Glomerulonephritis Glomerulonephritis (HP:0000099)
Show evidence (1 reference)
PMID:33186245 SUPPORT Human Clinical
"In profound organs such as the kidneys, CG deposition is less temperature-dependent, favored by local protein and anion concentrations, and can lead to glomerulonephritis."
This supports cryoglobulin-associated glomerulonephritis.
💊

Treatments

5
Etiology-directed antiviral therapy for HCV-associated disease
Action: Pharmacotherapy NCIT:C15986
Agent: direct-acting antiviral agent ↗
HCV-positive CV is treated with direct-acting antiviral agents to remove viral stimulation and induce sustained virologic response.
Show evidence (1 reference)
PMID:35348938 SUPPORT Human Clinical
"All HCV-positive CV patients should be given direct-acting antiviral agents (DAAs) that are consistently able to induce a sustained virologic response (SVR)."
This supports DAA therapy for HCV-associated CV.
Rituximab for persistent, severe, or refractory CV
Action: Pharmacotherapy NCIT:C15986
Agent: rituximab ↗
Anti-CD20 B-cell depletion is used for persistent, relapsing, severe, or refractory cryoglobulinemic vasculitis, often alongside etiology-directed therapy.
Show evidence (2 references)
PMID:37916482 SUPPORT Human Clinical
"Removing viral stimulation on B-cells through direct-acting antivirals and blocking B-cells proliferation and differentiation with rituximab are the goals of treatment of CV."
This supports both antiviral and rituximab treatment rationales.
PMID:37959271 SUPPORT Human Clinical
"The results consistently demonstrated the efficacy of rituximab, whether as a standalone treatment or as part of a therapeutic regimen."
This systematic review supports rituximab efficacy in HCV-associated CV.
Glucocorticoids for acute vasculitis control
Action: Pharmacotherapy NCIT:C15986
Agent: glucocorticoid ↗
Glucocorticoids can mitigate active vasculitis, but they are not modeled as maintenance therapy.
Show evidence (1 reference)
PMID:35348938 SUPPORT Human Clinical
"Glucocorticoids (GCs) can mitigate CV-associated vasculitis, but they have no role as maintenance therapy."
This supports glucocorticoids for vasculitis control while avoiding overstatement as maintenance therapy.
Cyclophosphamide for hyperactive severe disease
Action: Pharmacotherapy NCIT:C15986
Agent: cyclophosphamide ↗
Cyclophosphamide may be used in selected hyperactive phases or post-apheresis rebound contexts.
Show evidence (1 reference)
PMID:35348938 SUPPORT Human Clinical
"Cyclophosphamide restrains the hyperactive phase(s) of the disease and the post-apheresis rebound of newly synthesized CGs."
This supports cyclophosphamide as a selected therapy in severe hyperactive disease phases.
Therapeutic apheresis for hyperviscosity syndrome
Action: plasmapheresis Ontology label: Plasmapheresis NCIT:C15304
Therapeutic apheresis is used as emergency treatment for hyperviscosity syndrome in cryoglobulinemic vasculitis.
Target Phenotypes: Hyperviscosity syndrome
Show evidence (1 reference)
PMID:35348938 SUPPORT Human Clinical
"Therapeutic apheresis is an emergency treatment for CV patients with hyperviscosity syndrome."
This supports emergency apheresis for hyperviscosity-associated severe CV.
🔬

Biochemical Markers

4
Serum cryoglobulins (Positive)
Context: Repeated serum cryoglobulin positivity is the essential laboratory condition for classifying cryoglobulinemic vasculitis.
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"Positivity of serum cryoglobulins was defined by experts as an essential condition for CV classification."
This supports serum cryoglobulin positivity as a core biochemical diagnostic feature.
Low C4 complement (DECREASED)
Context: Low C4 is part of the laboratory classification domain in cryoglobulinemic vasculitis.
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"Reduced C4 levels, positive RF and the presence of serum M component (present in type I or II cryoglobulins, or detected by serum protein electrophoresis and immunofixation) were the laboratory items selected by the multivariate analysis"
This identifies reduced C4 as a selected laboratory item for CV classification.
Rheumatoid factor (Positive)
Context: Rheumatoid factor positivity helps classify mixed cryoglobulinemic vasculitis.
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"Reduced C4 levels, positive RF and the presence of serum M component (present in type I or II cryoglobulins, or detected by serum protein electrophoresis and immunofixation) were the laboratory items selected by the multivariate analysis"
This identifies positive rheumatoid factor as a laboratory classification item.
Serum M component (Positive)
Context: Serum M component, detected by serum protein electrophoresis or immunofixation, is a laboratory classification item in CV and is present in type I or type II cryoglobulins.
Show evidence (1 reference)
PMID:21571735 SUPPORT Human Clinical
"Reduced C4 levels, positive RF and the presence of serum M component (present in type I or II cryoglobulins, or detected by serum protein electrophoresis and immunofixation) were the laboratory items selected by the multivariate analysis"
This identifies serum M component as one of three selected laboratory classification items for CV.
{ }

Source YAML

click to show 
name: Cryoglobulinemic Vasculitis
creation_date: "2026-05-05T11:41:54Z"
updated_date: "2026-05-05T13:03:30Z"
description: >-
  Cryoglobulinemic vasculitis is an immune-complex mediated small-vessel
  vasculitis characterized by circulating cryoglobulins. Pathogenic
  cryoglobulins and B-cell clones form immune complexes that deposit on vascular
  endothelium, activate inflammatory pathways, and produce purpura, arthralgia,
  arthritis, peripheral neuropathy, glomerulonephritis, and other systemic
  manifestations.
category: Complex
disease_term:
  preferred_term: Cryoglobulinemic vasculitis
  term:
    id: MONDO:0007407
    label: Cryoglobulinemic vasculitis
parents:
- Vascular disorder
synonyms:
- Mixed cryoglobulinemia
- Essential mixed cryoglobulinemia
- Meltzer syndrome
has_subtypes:
- name: Type I
  display_name: Type I cryoglobulinemic vasculitis
  classification: immunoglobulin_composition
  subtype_term:
    preferred_term: Type I cryoglobulinemic vasculitis
  description: >-
    Type I disease is associated with immunoglobulins without rheumatoid-factor
    activity and often reflects monoclonal cryoglobulins from B-cell
    lymphoproliferative disease.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      immune complexes composed of rheumatoid factor (RF) monoclonal or polyclonal against polyclonal IgG (type II or type III cryoglobulins, respectively) or immunoglobulins without RF activity (type I)
    explanation: This defines type I cryoglobulins separately from mixed type II and III cryoglobulins.
- name: Type II
  display_name: Type II mixed cryoglobulinemic vasculitis
  classification: immunoglobulin_composition
  subtype_term:
    preferred_term: Type II mixed cryoglobulinemic vasculitis
  description: >-
    Type II mixed disease contains monoclonal rheumatoid factor activity
    against polyclonal IgG and is frequently associated with chronic hepatitis C
    infection or other B-cell stimulation.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      immune complexes composed of rheumatoid factor (RF) monoclonal or polyclonal against polyclonal IgG (type II or type III cryoglobulins, respectively)
    explanation: This defines type II and type III mixed cryoglobulins as RF-containing immune complexes against polyclonal IgG.
- name: Type III
  display_name: Type III mixed cryoglobulinemic vasculitis
  classification: immunoglobulin_composition
  subtype_term:
    preferred_term: Type III mixed cryoglobulinemic vasculitis
  description: >-
    Type III mixed disease contains polyclonal rheumatoid-factor activity
    against polyclonal IgG and is often linked to autoimmune or chronic
    inflammatory immune stimulation.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      immune complexes composed of rheumatoid factor (RF) monoclonal or polyclonal against polyclonal IgG (type II or type III cryoglobulins, respectively)
    explanation: This defines type II and type III mixed cryoglobulins as RF-containing immune complexes against polyclonal IgG.
pathophysiology:
- name: Cryoglobulin immune-complex vascular deposition
  description: >-
    Circulating cryoglobulins form pathogenic immune complexes that deposit on
    small-vessel endothelium and can trigger vasculitis or occlusive
    vasculopathy, especially in susceptible tissues and organs.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  downstream:
  - target: Immune-complex small-vessel vascular injury
    description: Immune-complex deposition activates inflammatory pathways and recruits leukocytes to small-vessel walls.
  evidence:
  - reference: PMID:37916482
    reference_title: "Cryoglobulinemic vasculitis: a 2023 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cryoglobulinemic vasculitis (CV) is an immune complex mediated small vessel vasculitis characterized by the presence of cryoglobulins in serum, often associated with hepatitis C infection, systemic autoimmune diseases or hematological conditions.
    explanation: This review directly defines CV as an immune-complex small-vessel vasculitis with circulating cryoglobulins.
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In vivo, in cold exposed tissues and organs, they can induce vasculitis and occlusive vasculopathy after deposition on vascular endothelium under low temperature and high concentration conditions.
    explanation: This supports endothelial deposition of cryoglobulins as a vascular lesion mechanism.
- name: B-cell clonal immune-complex production
  description: >-
    In infectious and noninfectious type II or type III disease, pathogenic
    B-cell clones produce immune complexes that drive small-vessel vasculitis;
    this explains the therapeutic rationale for antiviral removal of B-cell
    stimulation and anti-CD20 B-cell depletion.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  biological_processes:
  - preferred_term: B cell proliferation
    modifier: INCREASED
    term:
      id: GO:0042100
      label: B cell proliferation
  - preferred_term: immunoglobulin production
    modifier: INCREASED
    term:
      id: GO:0002377
      label: immunoglobulin production
  downstream:
  - target: Cryoglobulin immune-complex vascular deposition
    description: Pathogenic B-cell clones provide the immune-complex substrate for vascular deposition and inflammation.
  evidence:
  - reference: PMID:37916482
    reference_title: "Cryoglobulinemic vasculitis: a 2023 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Specific B-cell clones are involved in the production of pathogenic immune complexes that leads to small-vessel vasculitis.
    explanation: This supports pathogenic B-cell immune-complex production as a disease mechanism.
- name: Immune-complex small-vessel vascular injury
  description: >-
    Immune-complex deposition, complement consumption, and polymorphonuclear
    neutrophil activation are associated with vessel-wall inflammation,
    producing purpura, neuropathy, renal disease, and other systemic
    small-vessel manifestations.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: complement activation, classical pathway
    modifier: INCREASED
    term:
      id: GO:0006958
      label: complement activation, classical pathway
  evidence:
  - reference: DOI:10.3389/fmed.2023.1103065
    reference_title: Pathophysiology and clinical manifestations of immune complex vasculitides
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Serum sickness and CV fulfill the criteria of a type III hypersensitivity immune reaction as large lattices of the IC precipitate at vessel walls and activate polymorphonuclear neutrophils (PMNs).
    explanation: This directly supports immune-complex precipitation at vessel walls with neutrophil activation in CV.
  - reference: PMID:18796155
    reference_title: Mixed cryoglobulinemia.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Circulating mixed cryoglobulins, low C4 levels and orthostatic skin purpura are the hallmarks of the disease. Leukocytoclastic vasculitis involving medium- and, more often, small-sized blood vessels is the typical pathological finding, easily detectable by means of skin biopsy of recent vasculitic lesions.
    explanation: Low C4 supports complement consumption, while leukocytoclastic small-vessel vasculitis supports the downstream vascular-injury phenotype.
- name: Cryoprotein occlusive vasculopathy and hyperviscosity
  subtypes:
  - Type I
  description: >-
    Type I cryoglobulinemic vasculitis can include a cryoprotein-dominant
    occlusive vasculopathy and hyperviscosity presentation in addition to
    inflammatory small-vessel vasculitis.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  downstream:
  - target: Hyperviscosity syndrome
    description: Cryoprotein vascular effects can manifest clinically as hyperviscosity syndrome.
  evidence:
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In vivo, in cold exposed tissues and organs, they can induce vasculitis and occlusive vasculopathy after deposition on vascular endothelium under low temperature and high concentration conditions.
    explanation: This supports cryoglobulin deposition causing occlusive vasculopathy at vascular endothelium.
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      vascular involvement (purpura, skin ulcers, necrotic skin lesions or necrotising vasculitis biopsy-proven, Raynaud's phenomenon, or hyperviscosity syndrome according to clinical features and plasma viscosity test)
    explanation: This supports hyperviscosity syndrome as a vascular manifestation considered in CV classification.
histopathology:
- name: Biopsy-proven necrotising vasculitis
  diagnostic: true
  description: Biopsy evidence of necrotising vasculitis is a clinical classification item for cryoglobulinemic vasculitis.
  finding_term:
    preferred_term: necrotising vasculitis biopsy-proven
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      vascular involvement (purpura, skin ulcers, necrotic skin lesions or necrotising vasculitis biopsy-proven, Raynaud's phenomenon, or hyperviscosity syndrome according to clinical features and plasma viscosity test)
    explanation: This classification item supports biopsy-proven necrotising vasculitis as a diagnostic histopathologic finding.
phenotypes:
- category: Dermatologic
  name: Palpable purpura
  diagnostic: true
  description: Palpable purpura is a classic cutaneous manifestation of small-vessel immune-complex vasculitis.
  phenotype_term:
    preferred_term: Palpable purpura
    term:
      id: HP:0031363
      label: Palpable purpura
  evidence:
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs).
    explanation: This directly supports purpura as a cutaneous manifestation of CV.
- category: Dermatologic
  name: Skin ulcer
  description: Cutaneous disease can include ulcers.
  phenotype_term:
    preferred_term: Skin ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
  evidence:
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs).
    explanation: This review lists ulcers among cutaneous manifestations.
- category: Dermatologic
  name: Livedo reticularis
  description: Livedo reticularis is a cutaneous vascular manifestation of CV.
  phenotype_term:
    preferred_term: Livedo reticularis
    term:
      id: HP:0033505
      label: Livedo reticularis
  evidence:
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs).
    explanation: This review explicitly lists livedo reticularis among cutaneous manifestations of CV.
- category: Constitutional
  name: Fatigue
  description: Fatigue or asthenia is a cardinal constitutional manifestation in CV and part of the classic Meltzer triad.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Constitutional symptoms fatigue, low-grade fever (37–37.9°C for more than 10 days) or fever (≥38°C), or fibromyalgia,16 articular involvement
    explanation: This classification item supports fatigue as a constitutional manifestation of cryoglobulinemic vasculitis.
- category: Vascular
  name: Raynaud phenomenon
  description: Raynaud phenomenon is a vascular involvement item in cryoglobulinemic vasculitis classification.
  phenotype_term:
    preferred_term: Raynaud phenomenon
    term:
      id: HP:0030880
      label: Raynaud phenomenon
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      vascular involvement (purpura, skin ulcers, necrotic skin lesions or necrotising vasculitis biopsy-proven, Raynaud's phenomenon, or hyperviscosity syndrome according to clinical features and plasma viscosity test)
    explanation: This classification item explicitly includes Raynaud phenomenon as vascular involvement in CV.
- category: Vascular
  name: Hyperviscosity syndrome
  subtype: Type I
  description: Type I cryoglobulinemia can produce hyperviscosity syndrome requiring urgent plasma exchange or apheresis.
  phenotype_term:
    preferred_term: Hyperviscosity syndrome
  review_notes: >-
    Local HP and MONDO lookup did not expose a specific hyperviscosity syndrome
    phenotype term, so this remains preferred-term-only.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      vascular involvement (purpura, skin ulcers, necrotic skin lesions or necrotising vasculitis biopsy-proven, Raynaud's phenomenon, or hyperviscosity syndrome according to clinical features and plasma viscosity test)
    explanation: This classification item explicitly includes hyperviscosity syndrome as vascular involvement in CV.
- category: Musculoskeletal
  name: Arthralgia
  description: Arthralgia is a rheumatologic manifestation in CV.
  phenotype_term:
    preferred_term: Arthralgia
    term:
      id: HP:0002829
      label: Arthralgia
  evidence:
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs).
    explanation: This review lists arthralgia among rheumatologic manifestations.
- category: Musculoskeletal
  name: Arthritis
  description: Arthritis is a rheumatologic manifestation in CV.
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
  evidence:
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs).
    explanation: This review lists arthritis among rheumatologic manifestations.
- category: Neurological
  name: Peripheral neuropathy
  description: Peripheral neuropathy with paresthesia or lower-limb pain can occur in CV.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical manifestations are cutaneous (purpura, ulcers, vasomotor symptoms, and livedo reticularis), rheumatological (arthralgia and arthritis), and peripheral neuropathy (paresthesia and pain in the lower limbs).
    explanation: This directly supports peripheral neuropathy in CV.
- category: Renal
  name: Glomerulonephritis
  description: Cryoglobulin deposition in the kidney can lead to glomerulonephritis.
  phenotype_term:
    preferred_term: Glomerulonephritis
    term:
      id: HP:0000099
      label: Glomerulonephritis
  evidence:
  - reference: PMID:33186245
    reference_title: "Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In profound organs such as the kidneys, CG deposition is less temperature-dependent, favored by local protein and anion concentrations, and can lead to glomerulonephritis.
    explanation: This supports cryoglobulin-associated glomerulonephritis.
biochemical:
- name: Serum cryoglobulins
  presence: Positive
  context: >-
    Repeated serum cryoglobulin positivity is the essential laboratory
    condition for classifying cryoglobulinemic vasculitis.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Positivity of serum cryoglobulins was defined by experts as an essential condition for CV classification.
    explanation: This supports serum cryoglobulin positivity as a core biochemical diagnostic feature.
- name: Low C4 complement
  presence: DECREASED
  context: Low C4 is part of the laboratory classification domain in cryoglobulinemic vasculitis.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Reduced C4 levels, positive RF and the presence of serum M component (present in type I or II cryoglobulins, or detected by serum protein electrophoresis and immunofixation) were the laboratory items selected by the multivariate analysis
    explanation: This identifies reduced C4 as a selected laboratory item for CV classification.
- name: Rheumatoid factor
  presence: Positive
  context: Rheumatoid factor positivity helps classify mixed cryoglobulinemic vasculitis.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Reduced C4 levels, positive RF and the presence of serum M component (present in type I or II cryoglobulins, or detected by serum protein electrophoresis and immunofixation) were the laboratory items selected by the multivariate analysis
    explanation: This identifies positive rheumatoid factor as a laboratory classification item.
- name: Serum M component
  presence: Positive
  context: >-
    Serum M component, detected by serum protein electrophoresis or
    immunofixation, is a laboratory classification item in CV and is present in
    type I or type II cryoglobulins.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Reduced C4 levels, positive RF and the presence of serum M component (present in type I or II cryoglobulins, or detected by serum protein electrophoresis and immunofixation) were the laboratory items selected by the multivariate analysis
    explanation: This identifies serum M component as one of three selected laboratory classification items for CV.
diagnosis:
- name: Integrated cryoglobulinemic vasculitis classification
  description: >-
    Diagnosis and classification integrate serum cryoglobulin positivity with
    clinical manifestations and laboratory features such as low C4, rheumatoid
    factor positivity, and serum M component characterization.
  results: >-
    Positive cryoglobulins plus at least two questionnaire, clinical, or
    laboratory domains supports cryoglobulinemic vasculitis classification.
  evidence:
  - reference: PMID:21571735
    reference_title: Preliminary classification criteria for the cryoglobulinaemic vasculitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The final classification criteria for CV, by pooling data from group A and group B, required the positivity of questionnaire plus clinical, questionnaire plus laboratory, or clinical plus laboratory items, or all the three
    explanation: This states the integrated classification domain requirement for CV.
treatments:
- name: Etiology-directed antiviral therapy for HCV-associated disease
  description: >-
    HCV-positive CV is treated with direct-acting antiviral agents to remove
    viral stimulation and induce sustained virologic response.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: direct-acting antiviral agent
      term:
        id: NCIT:C281
        label: Antiviral Agent
  evidence:
  - reference: PMID:35348938
    reference_title: The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All HCV-positive CV patients should be given direct-acting antiviral agents (DAAs) that are consistently able to induce a sustained virologic response (SVR).
    explanation: This supports DAA therapy for HCV-associated CV.
- name: Rituximab for persistent, severe, or refractory CV
  description: >-
    Anti-CD20 B-cell depletion is used for persistent, relapsing, severe, or
    refractory cryoglobulinemic vasculitis, often alongside etiology-directed
    therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
  evidence:
  - reference: PMID:37916482
    reference_title: "Cryoglobulinemic vasculitis: a 2023 update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Removing viral stimulation on B-cells through direct-acting antivirals and blocking B-cells proliferation and differentiation with rituximab are the goals of treatment of CV.
    explanation: This supports both antiviral and rituximab treatment rationales.
  - reference: PMID:37959271
    reference_title: "Therapeutic Potential of Rituximab in Managing Hepatitis C-Associated Cryoglobulinemic Vasculitis: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The results consistently demonstrated the efficacy of rituximab, whether as a standalone treatment or as part of a therapeutic regimen.
    explanation: This systematic review supports rituximab efficacy in HCV-associated CV.
- name: Glucocorticoids for acute vasculitis control
  description: >-
    Glucocorticoids can mitigate active vasculitis, but they are not modeled as
    maintenance therapy.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: glucocorticoid
      term:
        id: CHEBI:24261
        label: glucocorticoid
  evidence:
  - reference: PMID:35348938
    reference_title: The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Glucocorticoids (GCs) can mitigate CV-associated vasculitis, but they have no role as maintenance therapy.
    explanation: This supports glucocorticoids for vasculitis control while avoiding overstatement as maintenance therapy.
- name: Cyclophosphamide for hyperactive severe disease
  description: Cyclophosphamide may be used in selected hyperactive phases or post-apheresis rebound contexts.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cyclophosphamide
      term:
        id: CHEBI:4027
        label: cyclophosphamide
  evidence:
  - reference: PMID:35348938
    reference_title: The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cyclophosphamide restrains the hyperactive phase(s) of the disease and the post-apheresis rebound of newly synthesized CGs.
    explanation: This supports cyclophosphamide as a selected therapy in severe hyperactive disease phases.
- name: Therapeutic apheresis for hyperviscosity syndrome
  description: Therapeutic apheresis is used as emergency treatment for hyperviscosity syndrome in cryoglobulinemic vasculitis.
  treatment_term:
    preferred_term: plasmapheresis
    term:
      id: NCIT:C15304
      label: Plasmapheresis
  target_phenotypes:
  - preferred_term: Hyperviscosity syndrome
  evidence:
  - reference: PMID:35348938
    reference_title: The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therapeutic apheresis is an emergency treatment for CV patients with hyperviscosity syndrome.
    explanation: This supports emergency apheresis for hyperviscosity-associated severe CV.
📚

References & Deep Research

Deep Research

1
Falcon ▸
Cryoglobulinemic Vasculitis (CryoVas): Comprehensive Disease Characteristics Report
Edison Scientific Literature 40 citations 2026-05-05T08:13:30.074874

Cryoglobulinemic Vasculitis (CryoVas): Comprehensive Disease Characteristics Report

Executive summary

Cryoglobulinemic vasculitis (CryoVas; also written “cryoglobulinaemic vasculitis”) is a systemic small-vessel vasculitis driven by circulating cryoglobulins—immunoglobulins that precipitate below 37 °C and resolubilize on warming—and consequent vascular immune-complex deposition and complement activation/consumption in mixed forms. The clinical spectrum ranges from the classic Meltzer triad (purpura, arthralgia, weakness) to life-/organ-threatening renal and neurologic disease. HCV historically accounted for most mixed CryoVas, but the DAA era has shifted the etiologic landscape toward autoimmune disease and lymphoproliferative disorders in many settings. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

1. Disease Information

1.1 Definition and current understanding

  • Cryoglobulins are “immunoglobulins that reversibly precipitate at temperatures below 37 °C” (definition used in modern reviews). (dammacco2023thewidespectrum pages 1-3)
  • Cryoglobulinemic vasculitis (CryoVas/CV) refers to a systemic vasculitic syndrome associated with cryoglobulin-containing immune complexes (mixed types) or cryoprotein-mediated vascular occlusion/hyperviscosity (type I), with manifestations from palpable purpura to severe neuropathy and glomerulonephritis. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3)

1.2 Common synonyms / alternative names

  • Cryoglobulinemic vasculitis; cryoglobulinaemic vasculitis (British spelling). (vita2011preliminaryclassificationcriteria pages 1-1)
  • Mixed cryoglobulinemic syndrome (MCS) / mixed cryoglobulinemia syndrome (used interchangeably in some clinical literature). (ferri2026cryoglobulinemiamonoclonaland pages 4-5)
  • Cryoglobulinemic syndrome / mixed cryoglobulinemia (often used historically; nomenclature harmonization has been proposed to distinguish lab finding vs clinical syndrome). (ferri2026cryoglobulinemiamonoclonaland pages 4-5, ferri2008orphanetjournalof pages 2-4)

1.3 Key identifiers (ICD/MeSH/MONDO/Orphanet)

Within the retrieved full-text corpus, formal ICD-10/ICD-11, MeSH, MONDO, and Orphanet ORPHA identifiers were not explicitly stated. The report therefore cannot provide evidence-backed codes from the available documents. (Limitation of current evidence set.)

1.4 Evidence source type

This report is derived from aggregated disease-level resources (systematic/narrative reviews, consensus recommendations, and classification-criteria studies) and selected cohort studies, rather than EHR-derived individual case aggregation. (dammacco2023thewidespectrum pages 1-3, rajendran2023riskfactorsfor pages 1-2, vita2011preliminaryclassificationcriteria pages 5-6)

2. Etiology

2.1 Primary causal factors / associated diseases

Cryoglobulinemia/CryoVas is etiologically heterogeneous, with major associated categories: 1. Infectious: especially hepatitis C virus (HCV) historically; also HBV and other infections. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5, mazzaro2023hepatitisbvirusinfection pages 1-2) 2. Autoimmune disease: e.g., Sjögren’s syndrome, systemic lupus erythematosus (SLE). (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5, roubertou2022cryoglobulinemiainsystemic pages 1-2) 3. B-cell lymphoproliferative disorders: dominant in type I cryoglobulinemia and important in mixed CryoVas (including risk of NHL). (ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5, dammacco2023thewidespectrum pages 1-3)

2.2 Classification (etiology-relevant)

Cryoglobulins are commonly classified by Brouet type: * Type I: single monoclonal Ig, associated with B-cell lymphoproliferative disorders. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3) * Type II (mixed): monoclonal IgM with RF activity + polyclonal IgG. (dammacco2023thewidespectrum pages 1-3) * Type III (mixed): polyclonal IgM/IgG. (dammacco2023thewidespectrum pages 1-3)

2.3 Risk factors (selected quantitative)

  • In type I cryoglobulinemia, >90% have an underlying lymphoproliferative disorder; MGUS frequency 36%–86%, overt hematologic malignancy 20%–64%. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)
  • In mixed CryoVas, HCV markers have historically been present in the majority of cases; one review notes anti-HCV positivity ranges widely across series. (cacoub2002cryoglobulinemiavasculitis. pages 2-3, dammacco2023thewidespectrum pages 1-3)

2.4 Protective factors

Evidence for explicit “protective factors” (genetic or environmental) was not identified in the retrieved corpus.

2.5 Gene–environment interactions

Mechanistic gene–environment interaction evidence (e.g., specific susceptibility loci interacting with infections) was not identified in the retrieved corpus.

3. Phenotypes

3.1 Core phenotype spectrum

  • Meltzer triad: purpura, arthralgia, weakness. (dammacco2023thewidespectrum pages 1-3, covic2023therapeuticpotentialof pages 1-3)
  • Cutaneous: palpable purpura; ulcers; digital ischemia; livedo; Raynaud phenomenon (not exhaustive). (covic2023therapeuticpotentialof pages 1-3, roubertou2022cryoglobulinemiainsystemic pages 1-2)
  • Neurologic: peripheral neuropathy; potentially severe neuropathy; occasional CNS involvement. (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3, roubertou2022cryoglobulinemiainsystemic pages 1-2)
  • Renal: membranoproliferative glomerulonephritis / cryoglobulinemic glomerulonephritis. (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3)

3.2 Frequency / severity (examples)

  • In an SLE cohort screened for cryoglobulins, 15% of cryoglobulin-positive patients developed CryoVas; severe manifestations were uncommon (GN 5%, CNS involvement 19%) with no deaths reported during follow-up. (roubertou2022cryoglobulinemiainsystemic pages 1-2)
  • In non-infectious CryoVas, relapse rates reported as ~28% in type I and 22%–60% in mixed NICV, with time-to-relapse 1–80 months. (rajendran2023riskfactorsfor pages 1-2)

3.3 Suggested HPO terms (examples; ontology suggestions)

(These are suggested mappings; the retrieved sources do not provide HPO IDs.) * Palpable purpura; skin ulcer; arthralgia; fatigue/asthenia; peripheral neuropathy; glomerulonephritis; Raynaud phenomenon; digital ischemia.

4. Genetic/Molecular Information

4.1 Causal genes / pathogenic variants

CryoVas is not primarily a monogenic disorder in typical adult presentations; the retrieved evidence emphasizes secondary causes (infection, autoimmunity, lymphoproliferation). Specific causal germline variants were not identified in the retrieved corpus. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

4.2 Molecular features highlighted in recent literature

  • Mixed CryoVas pathogenesis includes B-cell aberrant lymphoproliferation and autoantibody (RF) production, leading to immune complex formation and deposition. (ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

5. Environmental Information

5.1 Infectious agents

  • HCV is the dominant historical driver of mixed cryoglobulinemia/CryoVas; cryoglobulins are detectable in ~25–30% of HCV-infected individuals in one major review. (dammacco2023thewidespectrum pages 1-3)
  • HBV can cause CryoVas; European series estimate HBV-associated CryoVas prevalence among HBV patients 0.5%–5.5% (reviewed literature). (mazzaro2023hepatitisbvirusinfection pages 1-2)

5.2 Lifestyle/occupational exposures

Specific environmental toxin/lifestyle causal associations were not identified in the retrieved corpus.

6. Mechanism / Pathophysiology

6.1 Causal chain (high-level)

  1. Trigger/driver: chronic infection (esp. HCV historically), autoimmune disease, or monoclonal B-cell disorder. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)
  2. B-cell dysregulation with RF activity and production of cryoprecipitable immunoglobulins (mixed types). (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)
  3. Immune complex formation and deposition in small vessels → leukocytoclastic vasculitis and end-organ damage (skin, nerves, kidneys). (ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3)
  4. Complement consumption (often low C4) and systemic inflammation. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

Type I differs mechanistically, tending toward mechanical vascular occlusion/hyperviscosity rather than classic immune-complex vasculitis. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5)

6.2 Suggested GO/CL terms (examples; ontology suggestions)

  • GO biological processes: immune complex clearance; complement activation; B cell activation; leukocyte migration; vasculitis/inflammatory response.
  • CL cell types: B cell; plasma cell; neutrophil; monocyte/macrophage; endothelial cell.

7. Anatomical Structures Affected

7.1 Organ/tissue involvement

  • Skin (purpura, ulcers, digital ischemia). (dammacco2023thewidespectrum pages 1-3, roubertou2022cryoglobulinemiainsystemic pages 1-2)
  • Peripheral nervous system (peripheral neuropathy). (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3)
  • Kidney (membranoproliferative glomerulonephritis). (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3)

7.2 Suggested UBERON terms (examples; ontology suggestions)

Skin; peripheral nerve; kidney glomerulus; small blood vessel.

8. Temporal Development

8.1 Onset/course

  • Typical onset is adult (reviews cite age ranges such as 45–65 in NICV contexts). (rajendran2023riskfactorsfor pages 2-3)
  • Course can be relapsing; relapse timing reported from 1 to 80 months in NICV. (rajendran2023riskfactorsfor pages 1-2)

9. Inheritance and Population

9.1 Epidemiology

  • Essential mixed cryoglobulinemia prevalence reported as ~1:100,000 and female:male ratio ~3:1 in an Orphanet-style review article. (ferri2008orphanetjournalof pages 1-2)
  • In HCV infection, cryoglobulin positivity varies widely by cohort; a large HCV prospective cohort found mixed cryoglobulin in 40%. (cacoub2002cryoglobulinemiavasculitis. pages 2-3)
  • Severe symptomatic vasculitis is relatively uncommon among cryoglobulin-positive HCV patients; one review notes only ~2–3% develop severe vasculitis. (cacoub2002cryoglobulinemiavasculitis. pages 2-3)

9.2 Geographic distribution

Higher frequency in Southern Europe versus Northern Europe/North America is reported in older epidemiologic summaries. (ferri2008orphanetjournalof pages 1-2)

10. Diagnostics

10.1 Classification criteria (De Vita et al.)

The De Vita 2011 classification framework requires (i) documented cryoglobulins and (ii) positivity in at least 2 of 3 domains (questionnaire, clinical, laboratory), with reported sensitivity ~88.5% and specificity ~93.6% in key comparisons. (vita2011preliminaryclassificationcriteria pages 5-6, vita2011preliminaryclassificationcriteria pages 1-1)

A cropped figure from the original paper is available and summarizes the domains and thresholds. (vita2011preliminaryclassificationcriteria media 2dc84f3a)

10.2 Laboratory testing: cryoglobulin pre-analytics (critical for avoiding false negatives)

Multiple laboratory best-practice sources emphasize that cryoglobulin testing is highly sensitive to pre-analytical temperature control: * Maintain whole blood at ~37 °C from collection through clotting and serum separation; use pre-warmed tubes and warm transport (e.g., thermos). (sargur2010cryoglobulinevaluationbest pages 4-5, motyckova2011laboratorytestingfor pages 1-2, bakker2003adequatesamplingin pages 1-2) * Typical protocols include clotting at 37 °C for ~1 hour, separation (preferably warm centrifugation), then serum incubation at 4 °C for 3–7 days to allow precipitation (type II/III may take up to a week). (sargur2010cryoglobulinevaluationbest pages 4-5, motyckova2011laboratorytestingfor pages 2-3, patel2024evaluationofcryoprotein pages 5-6) * Insufficient volume (e.g., <10 mL) and temperature drops can cause false negatives. (mariscalrodriguez2019laboratoryguidelinesfor pages 4-5)

10.3 Common supportive biomarkers/tests

  • Low complement (esp. low C4) and RF positivity are common in mixed CryoVas and are part of classification laboratory domains. (vita2011preliminaryclassificationcriteria pages 3-4)
  • Demonstration of cryoglobulin type (immunofixation) is essential to distinguish type I versus mixed and guide etiologic work-up. (dammacco2023thewidespectrum pages 1-3, motyckova2011laboratorytestingfor pages 2-3)

10.4 Differential diagnosis (high-level)

CryoVas is within immune-complex small-vessel vasculitis differential; formal differentials were not comprehensively extractable from the retrieved corpus.

11. Outcome / Prognosis

11.1 Survival/mortality

  • A DAA-era narrative synthesis reports mortality about ~25% at 5 years and ~40% at 10 years for HCV-associated CryoVas; and 10-year survival differences by subtype (HCV-positive mixed 63%, HCV-negative mixed 65%, type I 87%)—these estimates should be interpreted cautiously as they are review-level summaries rather than a single prospective cohort. (balta2025impactofdirectacting pages 5-6)

11.2 Relapse and prognostic factors

  • NICV relapse rates: ~28% in type I and 22–60% in mixed NICV (systematic review). (rajendran2023riskfactorsfor pages 1-2)
  • Factors associated with relapse/death in NICV syntheses include incomplete immunologic response (e.g., failure to normalize C4 and reduce/disappear cryoglobulins), and severe organ involvement (e.g., renal insufficiency, pulmonary/GI involvement) and older age. (rajendran2023riskfactorsfor pages 1-2, rajendran2023riskfactorsfor pages 2-3)

12. Treatment

12.1 Current standard approaches (real-world implementation)

Treatment is commonly framed as a three-pronged strategy: 1. Treat underlying cause (e.g., antivirals for HCV; nucleos(t)ide analogues for HBV). (covic2023therapeuticpotentialof pages 1-3, mazzaro2023hepatitisbvirusinfection pages 1-2) 2. B-cell–targeted therapy (rituximab) for moderate–severe disease, persistent disease after viral clearance, contraindications to antivirals, or organ-/life-threatening manifestations. (dammacco2023thewidespectrum pages 1-3, covic2023therapeuticpotentialof pages 1-3) 3. Plasma exchange/apheresis and intensive immunosuppression (high-dose glucocorticoids ± cyclophosphamide) for emergencies such as hyperviscosity or severe organ-threatening disease. (covic2023therapeuticpotentialof pages 1-3, dammacco2023thewidespectrum pages 1-3)

12.2 Antiviral therapy in HCV-associated CryoVas

  • Direct-acting antivirals (DAAs) are recommended broadly for HCV-positive CryoVas and achieve high SVR at population level; CryoVas manifestation resolution rates are variable across studies. (dammacco2023thewidespectrum pages 1-3, dammacco2023thewidespectrum pages 3-5)

12.3 Rituximab (anti-CD20)

  • Evidence syntheses indicate rituximab can induce remission in many mixed CryoVas patients and is used especially for severe disease or DAA-nonresponders/persistent vasculitis. (dammacco2023thewidespectrum pages 1-3, ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3)
  • In HCV-associated CryoVas, a systematic review reports trial-level results where rituximab achieved remission in 83.3% at 6 months in one trial compared with 8.3% control; and improved sustained response in combination with interferon-era antivirals. (covic2023therapeuticpotentialof pages 1-3)

12.4 Glucocorticoids and cyclophosphamide

  • Glucocorticoids may mitigate vasculitis acutely but are not considered maintenance therapy in some expert syntheses; cyclophosphamide use has been largely replaced by rituximab but remains relevant in severe cases. (dammacco2023thewidespectrum pages 1-3)

12.5 Plasma exchange / apheresis

  • Therapeutic apheresis is described as an emergency treatment in hyperviscosity syndrome. (dammacco2023thewidespectrum pages 1-3)

12.6 Emerging / experimental therapies

Evidence in the retrieved corpus highlights potential rescue options in rituximab-refractory nonviral CryoVas, including alkylators and biologics (e.g., rituximab + belimumab in small series). (ezconde2023nonviralcryoglobulinemicvasculitis pages 14-16)

12.7 Suggested MAXO terms (examples; ontology suggestions)

Antiviral therapy; B-cell depletion therapy (anti-CD20); therapeutic plasma exchange; glucocorticoid therapy; alkylating agent chemotherapy.

13. Prevention

Primary prevention is largely indirect via prevention/treatment of underlying causes (e.g., HCV treatment and HBV suppression). Explicit prevention trial evidence was not identified in the retrieved corpus.

14. Other Species / Natural Disease

No evidence for naturally occurring CryoVas analogs in non-human species was identified in the retrieved corpus.

15. Model Organisms

No specific model-organism systems were identified in the retrieved corpus.

Visual evidence: De Vita classification criteria figure

The following figure excerpt summarizes the three-domain De Vita classification criteria and the requirement for repeated cryoglobulin positivity. (vita2011preliminaryclassificationcriteria media 2dc84f3a)

Direct abstract quotes (selected)

  • Dammacco et al. 2023 (Clin Exp Med; published Mar 2023; https://doi.org/10.1007/s10238-022-00808-1): “Immunoglobulins that reversibly precipitate at temperatures below 37 °C are called cryoglobulins (CGs). Cryoglobulinemia often manifests as cryoglobulinemic vasculitis (CV), whose symptoms range in severity from purpuric eruptions to life-threatening features.” (dammacco2023thewidespectrum pages 1-3)
  • De Vita et al. 2011 (Ann Rheum Dis; published Jul 2011; https://doi.org/10.1136/ard.2011.150755): “Positivity of serum cryoglobulins was defined by experts as an essential condition for CV classification.” (vita2011preliminaryclassificationcriteria pages 1-1)

Evidence gaps / limitations

  1. Ontology/identifier codes (MONDO, ORPHA, ICD, MeSH) were not explicitly present in the retrieved full-text evidence; adding them would require direct database queries beyond the current paper corpus.
  2. Many quantitative outcome estimates for the DAA era are available mainly as review-level syntheses rather than uniformly reported prospective cohorts; where such estimates are used, they are attributed as such.
  3. Genetic susceptibility loci, protective factors, and model organism data were not found in the retrieved sources.

References

  1. (dammacco2023thewidespectrum pages 1-3): Franco Dammacco, Gianfranco Lauletta, and Angelo Vacca. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clinical and Experimental Medicine, 23:255-272, Mar 2023. URL: https://doi.org/10.1007/s10238-022-00808-1, doi:10.1007/s10238-022-00808-1. This article has 50 citations and is from a peer-reviewed journal.

  2. (ezconde2023nonviralcryoglobulinemicvasculitis pages 1-3): Andrea N úñ ez-Conde, Ignasi Rodr í guez-Pint ó, David A. Alba-Garibay, Alba Álvarez-Abella, Alba Jerez-Lienas, Oriol Llargu é s, M. Antonio, Alba-S á nchez, Diana Oleas, and Marco A Alba. Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice. Vessel Plus, Oct 2023. URL: https://doi.org/10.20517/2574-1209.2023.105, doi:10.20517/2574-1209.2023.105. This article has 3 citations.

  3. (ezconde2023nonviralcryoglobulinemicvasculitis pages 3-5): Andrea N úñ ez-Conde, Ignasi Rodr í guez-Pint ó, David A. Alba-Garibay, Alba Álvarez-Abella, Alba Jerez-Lienas, Oriol Llargu é s, M. Antonio, Alba-S á nchez, Diana Oleas, and Marco A Alba. Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice. Vessel Plus, Oct 2023. URL: https://doi.org/10.20517/2574-1209.2023.105, doi:10.20517/2574-1209.2023.105. This article has 3 citations.

  4. (vita2011preliminaryclassificationcriteria pages 1-1): S. Vita, F. Soldano, Miriam Isola, Giuseppe Monti, A. Gabrielli, A. Tzioufas, C. Ferri, G. Ferraccioli, L. Quartuccio, L. Corazza, G. D. Marchi, M. R. Casals, M. Voulgarelis, Marco Lenzi, Francesco Saccardo, P. Fraticelli, M. Mascia, D. Sansonno, P. Cacoub, M. Tomšič, A. Tavoni, M. Pietrogrande, A. Zignego, S. Scarpato, C. Mazzaro, Pietro Pioltelli, Serge Steinfeld, P. Lamprecht, S. Bombardieri, and M. Galli. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 70:1183-1190, Jul 2011. URL: https://doi.org/10.1136/ard.2011.150755, doi:10.1136/ard.2011.150755. This article has 214 citations and is from a highest quality peer-reviewed journal.

  5. (ferri2026cryoglobulinemiamonoclonaland pages 4-5): Clodoveo Ferri, Laura Gragnani, Anna Linda Zignego, and Dilia Giuggioli. Cryoglobulinemia, monoclonal and mixed cryoglobulinemia syndromes, cryoglobulinemic vasculitis: a proposal for comprehensive nomenclature and definition. Frontiers in Immunology, Feb 2026. URL: https://doi.org/10.3389/fimmu.2026.1754012, doi:10.3389/fimmu.2026.1754012. This article has 0 citations and is from a peer-reviewed journal.

  6. (ferri2008orphanetjournalof pages 2-4): C Ferri. Orphanet journal of rare. Unknown journal, 2008.

  7. (rajendran2023riskfactorsfor pages 1-2): Nithya Rajendran, Puteri Maisarah Rameli, and Hanaa Awad. Risk factors for relapse in non-infectious cryoglobulinemic vasculitis, including type i cryoglobulinemia: a systematic review. Frontiers in Immunology, Jul 2023. URL: https://doi.org/10.3389/fimmu.2023.1215345, doi:10.3389/fimmu.2023.1215345. This article has 4 citations and is from a peer-reviewed journal.

  8. (vita2011preliminaryclassificationcriteria pages 5-6): S. Vita, F. Soldano, Miriam Isola, Giuseppe Monti, A. Gabrielli, A. Tzioufas, C. Ferri, G. Ferraccioli, L. Quartuccio, L. Corazza, G. D. Marchi, M. R. Casals, M. Voulgarelis, Marco Lenzi, Francesco Saccardo, P. Fraticelli, M. Mascia, D. Sansonno, P. Cacoub, M. Tomšič, A. Tavoni, M. Pietrogrande, A. Zignego, S. Scarpato, C. Mazzaro, Pietro Pioltelli, Serge Steinfeld, P. Lamprecht, S. Bombardieri, and M. Galli. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 70:1183-1190, Jul 2011. URL: https://doi.org/10.1136/ard.2011.150755, doi:10.1136/ard.2011.150755. This article has 214 citations and is from a highest quality peer-reviewed journal.

  9. (mazzaro2023hepatitisbvirusinfection pages 1-2): Cesare Mazzaro, Riccardo Bomben, Marcella Visentini, Laura Gragnani, Luca Quartuccio, Francesco Saccardo, Marco Sebastiani, Davide Filippini, Gianfranco Lauletta, Giuseppe Monti, and Valter Gattei. Hepatitis b virus-infection related cryoglobulinemic vasculitis. clinical manifestations and the effect of antiviral therapy: a review of the literature. Frontiers in Oncology, Feb 2023. URL: https://doi.org/10.3389/fonc.2023.1095780, doi:10.3389/fonc.2023.1095780. This article has 12 citations.

  10. (roubertou2022cryoglobulinemiainsystemic pages 1-2): Yoann Roubertou, Sabine Mainbourg, Arnaud Hot, Denis Fouque, Cyrille Confavreux, Roland Chapurlat, Sébastien Debarbieux, Denis Jullien, Pascal Sève, Laurent Juillard, Marie-Nathalie Kolopp-Sarda, and Jean-Christophe Lega. Cryoglobulinemia in systemic lupus erythematosus: a retrospective study of 213 patients. Arthritis Research & Therapy, Jul 2022. URL: https://doi.org/10.1186/s13075-022-02857-z, doi:10.1186/s13075-022-02857-z. This article has 18 citations and is from a domain leading peer-reviewed journal.

  11. (cacoub2002cryoglobulinemiavasculitis. pages 2-3): Patrice Cacoub, Nathalie Costedoat-Chalumeau, Olivier Lidove, and Laurent Alric. Cryoglobulinemia vasculitis. Current opinion in rheumatology, 14 1:29-35, Jan 2015. URL: https://doi.org/10.1097/00002281-200201000-00006, doi:10.1097/00002281-200201000-00006. This article has 354 citations and is from a peer-reviewed journal.

  12. (covic2023therapeuticpotentialof pages 1-3): Andreea Covic, Irina Draga Caruntu, Alexandru Burlacu, Simona Eliza Giusca, Adrian Covic, Anca Elena Stefan, Crischentian Brinza, and Gener Ismail. Therapeutic potential of rituximab in managing hepatitis c-associated cryoglobulinemic vasculitis: a systematic review. Journal of Clinical Medicine, 12:6806, Oct 2023. URL: https://doi.org/10.3390/jcm12216806, doi:10.3390/jcm12216806. This article has 7 citations.

  13. (rajendran2023riskfactorsfor pages 2-3): Nithya Rajendran, Puteri Maisarah Rameli, and Hanaa Awad. Risk factors for relapse in non-infectious cryoglobulinemic vasculitis, including type i cryoglobulinemia: a systematic review. Frontiers in Immunology, Jul 2023. URL: https://doi.org/10.3389/fimmu.2023.1215345, doi:10.3389/fimmu.2023.1215345. This article has 4 citations and is from a peer-reviewed journal.

  14. (ferri2008orphanetjournalof pages 1-2): C Ferri. Orphanet journal of rare. Unknown journal, 2008.

  15. (vita2011preliminaryclassificationcriteria media 2dc84f3a): S. Vita, F. Soldano, Miriam Isola, Giuseppe Monti, A. Gabrielli, A. Tzioufas, C. Ferri, G. Ferraccioli, L. Quartuccio, L. Corazza, G. D. Marchi, M. R. Casals, M. Voulgarelis, Marco Lenzi, Francesco Saccardo, P. Fraticelli, M. Mascia, D. Sansonno, P. Cacoub, M. Tomšič, A. Tavoni, M. Pietrogrande, A. Zignego, S. Scarpato, C. Mazzaro, Pietro Pioltelli, Serge Steinfeld, P. Lamprecht, S. Bombardieri, and M. Galli. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 70:1183-1190, Jul 2011. URL: https://doi.org/10.1136/ard.2011.150755, doi:10.1136/ard.2011.150755. This article has 214 citations and is from a highest quality peer-reviewed journal.

  16. (sargur2010cryoglobulinevaluationbest pages 4-5): Ravishankar Sargur, Peter White, and William Egner. Cryoglobulin evaluation: best practice? Annals of Clinical Biochemistry, 47:16-8, Jan 2010. URL: https://doi.org/10.1258/acb.2009.009180, doi:10.1258/acb.2009.009180. This article has 153 citations and is from a peer-reviewed journal.

  17. (motyckova2011laboratorytestingfor pages 1-2): Gabriela Motyckova and Mandakolathur Murali. Laboratory testing for cryoglobulins. American Journal of Hematology, 86:500-502, Jun 2011. URL: https://doi.org/10.1002/ajh.22023, doi:10.1002/ajh.22023. This article has 136 citations and is from a domain leading peer-reviewed journal.

  18. (bakker2003adequatesamplingin pages 1-2): Andries J. Bakker, Jennichjen Slomp, Taede de Vries, Dick A.G. Boymans, Bert Veldhuis, Kees Halma, and Peter Joosten. Adequate sampling in cryoglobulinaemia: recommended warmly. Clinical Chemistry and Laboratory Medicine, 41:85-89, Jan 2003. URL: https://doi.org/10.1515/cclm.2003.015, doi:10.1515/cclm.2003.015. This article has 29 citations and is from a peer-reviewed journal.

  19. (motyckova2011laboratorytestingfor pages 2-3): Gabriela Motyckova and Mandakolathur Murali. Laboratory testing for cryoglobulins. American Journal of Hematology, 86:500-502, Jun 2011. URL: https://doi.org/10.1002/ajh.22023, doi:10.1002/ajh.22023. This article has 136 citations and is from a domain leading peer-reviewed journal.

  20. (patel2024evaluationofcryoprotein pages 5-6): Dina Patel, Ravishankar Sargur, Joanna Sheldon, Rachel D Wheeler, and Carol Stanley. Evaluation of cryoprotein investigation using a digital external quality assurance scheme. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 61:347-355, Mar 2024. URL: https://doi.org/10.1177/00045632241239805, doi:10.1177/00045632241239805. This article has 3 citations.

  21. (mariscalrodriguez2019laboratoryguidelinesfor pages 4-5): A. Mariscal-Rodríguez, L.M. Villar Guimerans, M. López-Trascasa, M. Hernández González, and E. Moga Naranjo. Laboratory guidelines for the diagnosis of patients with cryoglobulinemic syndrome. Revista Clinica Espanola, 219:505-513, Dec 2019. URL: https://doi.org/10.1016/j.rceng.2019.01.003, doi:10.1016/j.rceng.2019.01.003. This article has 6 citations and is from a peer-reviewed journal.

  22. (vita2011preliminaryclassificationcriteria pages 3-4): S. Vita, F. Soldano, Miriam Isola, Giuseppe Monti, A. Gabrielli, A. Tzioufas, C. Ferri, G. Ferraccioli, L. Quartuccio, L. Corazza, G. D. Marchi, M. R. Casals, M. Voulgarelis, Marco Lenzi, Francesco Saccardo, P. Fraticelli, M. Mascia, D. Sansonno, P. Cacoub, M. Tomšič, A. Tavoni, M. Pietrogrande, A. Zignego, S. Scarpato, C. Mazzaro, Pietro Pioltelli, Serge Steinfeld, P. Lamprecht, S. Bombardieri, and M. Galli. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Annals of the Rheumatic Diseases, 70:1183-1190, Jul 2011. URL: https://doi.org/10.1136/ard.2011.150755, doi:10.1136/ard.2011.150755. This article has 214 citations and is from a highest quality peer-reviewed journal.

  23. (balta2025impactofdirectacting pages 5-6): Alexia Anastasia Stefania Balta, Mariana Daniela Ignat, Raisa Eloise Barbu, Caterina Dumitru, Diana Sabina Radaschin, Valentin Bulza, Silvia Aura Mateescu Costin, Catalin Pleșea-Condratovici, and Liliana Baroiu. Impact of direct-acting antivirals on extrahepatic manifestations in chronic hepatitis c: a narrative review with a hermeneutic approach. Healthcare, 13:1953, Aug 2025. URL: https://doi.org/10.3390/healthcare13161953, doi:10.3390/healthcare13161953. This article has 4 citations.

  24. (dammacco2023thewidespectrum pages 3-5): Franco Dammacco, Gianfranco Lauletta, and Angelo Vacca. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clinical and Experimental Medicine, 23:255-272, Mar 2023. URL: https://doi.org/10.1007/s10238-022-00808-1, doi:10.1007/s10238-022-00808-1. This article has 50 citations and is from a peer-reviewed journal.

  25. (ezconde2023nonviralcryoglobulinemicvasculitis pages 14-16): Andrea N úñ ez-Conde, Ignasi Rodr í guez-Pint ó, David A. Alba-Garibay, Alba Álvarez-Abella, Alba Jerez-Lienas, Oriol Llargu é s, M. Antonio, Alba-S á nchez, Diana Oleas, and Marco A Alba. Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice. Vessel Plus, Oct 2023. URL: https://doi.org/10.20517/2574-1209.2023.105, doi:10.20517/2574-1209.2023.105. This article has 3 citations.